Summary( g! Z4 p( w: v- l1 U

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt and will significantly affect the Anti Hepatitis Virus Drugs market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Anti Hepatitis Virus Drugs industry.

Hepatitis is inflammation of the liver. The disease can be self-limiting or it can progress to fibrosis (scarring), cirrhosis, or liver cancer. Hepatitis virus is the most common cause of hepatitis in the world, but other infections, toxic substances (such as alcohol, certain drugs) and autoimmune diseases can also cause hepatitis.

In 2019, the global antiviral drug market was approximately US$ 56.4 billion, while Anti-hepatitis virus drugs accounted for 39%, closed to USD$ 22 billion.

Anti hepatitis virus brugs breakdown data by type can be segmented into Nucleos(t)ide Analogues, Direct-acting Antiviral Dgents (DAAs) and Interferon Alfa.

Recently, anti hepatitis virus drugs have received a lot of attention as potential Covid-19 treatments. Interferons have been used to treat autoimmune diseases and viral hepatitis. Since the outbreak of Covid-19, interferons have already been used to treat Covid-19 cases in China.

Figure 1.   Global Anti Hepatitis Virus Drugs Market Size (Value), (US$ Billion), 2015 VS 2019

Source: Secondary Sources, Expert Interviews and QYResearch, 2020

The following players are covered in this report: Novartis, Roche, Bristol Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, AbbVie, Gilead Sciences, CHIATAI TIANQING, Cosunter Pharmaceutical, Qingfeng Pharmaceutical, etc.

Recently news, Gilead Sciences is developing a kind of Nucleos(t)ide Analogues, Remdesivir. Remdesivir is a 1′-cyano-substituted adenosine nucleotide analogue with broad-spectrum antiviral activity against various RNA viruses. It is developed by Gilead Sciences for the treatment of Covid-19, a coronavirus disease, and Ebola virus infection.

There are five major hepatitis viruses, called A, B, C, D and E types. These five types of hepatitis viruses have caused great concern because of the disease and death burden and the possibility of outbreaks and epidemics caused by them. In particular, type B and type C cause hundreds of millions of people to suffer from chronic diseases, and together become the most common cause of cirrhosis and cancer.

Table 1.   Comparison of Five Hepatitis Viruses

　#

Hepatitis A   virus

Hepatitis B   virus

Hepatitis C   virus

Hepatitis D   virus

Hepatitis E   virus

Virus   Abbreviation

HAV

HBV

HCV

HDV

HEV

Section

Hepatitis A virus

Hepatoviridae

Flaviviridae

None

Calicivirus

Genus

Hepatovirus

Orthohepatotropic DNA virus

Hepatitis C virus

Hepatitis D virus

None

Virions

24nm, Icosahedral

42nm, Spherical

60nm, Spherical

3nm, Spherical

30-32nm, Icosahedral

Envelope   Protein

No

HBsAg

No

HBsAg

No

Genome

ssRNA

dsDNA

ssRNA

ssRNA

ssRNA

Self-Limiteing

Yes

No

No

No

Yes

Popularity

High

High

Medium

Low

Part

Vaccine

Yes

Yes

No

No

Yes

Way For   Spreading

Fecal–Oral Route

Mother-to-child、Blood   spread、Sexual transmission

Blood spread, etc

Blood spread

Fecal–Oral Route

Source: Secondary Sources, Expert Interviews and QYResearch, 2020

According to WHO, Viral hepatitis B and C are major health challenges, affecting 325 million people globally. They are root causes of liver cancer, leading to 1.34 million deaths every year. Hepatitis B and C are chronic infections that may not show symptoms for a long period, sometimes years or decades. At least 60% of liver cancer cases are due to late testing and treatment of viral hepatitis B and C. Low coverage of testing and treatment is the most important gap to be addressed in order to achieve the global elimination goals by 2030.

Figure 2.   Global and Chinese Number of Chronic HBV Infections Comparison in 2018 (Million Person)

Source: Secondary Sources, Expert Interviews and QYResearch, 2020

Around 3.5% of the world’s population is infected with HBV, especially in China, the disease burden is huge. Nearly one-third of the 257 million people living in the world live in China. A recent article in The Lancet claims that 10 million people will die by 2030.

Figure 3.   New Cases of Hepatitis C in China (2004-2019)

Source: Secondary Sources, Expert Interviews and QYResearch, 2020

Anti-hepatitis virus drugs have grown rapidly due to the intensified hepatitis B trend, among them, entecavir is the main treatment drug. However, due to price cuts and other policies, tenofovir, propofol and tenofovir have continued to increase. Under the continuing influence of the COVID-19, the use of related antiviral drugs will greatly increase, such as alpha-interferon, lopinavir / ritonavir, ribavirin, and redisevir, etc.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Anti Hepatitis Virus Drugs market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Anti Hepatitis Virus Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Anti Hepatitis Virus Drugs market in terms of revenue.

Players, stakeholders, and other participants in the global Anti Hepatitis Virus Drugs market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.

Regional and Country-level Analysis

The report offers an exhaustive geographical analysis of the global Anti Hepatitis Virus Drugs market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.

Competition Analysis

In the competitive analysis section of the report, leading as well as prominent players of the global Anti Hepatitis Virus Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Anti Hepatitis Virus Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Anti Hepatitis Virus Drugs market.

The following players are covered in this report:

Novartis

Roche

Bristol Myers Squibb

GlaxoSmithKline

Johnson & Johnson

Merck

AbbVie

Gilead Sciences

CHIATAI TIANQING

Cosunter Pharmaceutical

Qingfeng Pharmaceutical

Anti Hepatitis Virus Drugs Breakdown Data by Type

Nucleos(t)ide Analogues

Direct-acting Antiviral Dgents (DAAs)

Interferon Alfa

Anti Hepatitis Virus Drugs Breakdown Data by Application

Hepatitis B

HCV

Other

for more information

please go https://www.qyresearch.com/index ... -virus-drugs-market  

and you can go https://www.qyresearch.comto know more and more

if you need any help you can contact

qifeifei@qyresearch.com / telephone number ：18910840196

00861082945717

QY Research support best market reports for you.